Clinical and Functional Consequences of C-Terminal Variants in MCT8: A Case Series

Ferdy S. van Geest, Marcel E. Meima, Kyra E. Stuurman, Nicole I. Wolf, Marjo S. van der Knaap, Cláudia F. Lorea, Fabiano O. Poswar, Filippo Vairo, Nicola Brunetti-Pierri, Gerarda Cappuccio, Priyanka Bakhtiani, Sonja A. de Munnik, Robin P. Peeters, W. Edward Visser, Stefan Groeneweg

Research output: Contribution to JournalArticleAcademicpeer-review


CONTEXT: Genetic variants in SLC16A2, encoding the thyroid hormone transporter MCT8, can cause intellectual and motor disability and abnormal serum thyroid function tests, known as MCT8 deficiency. The C-terminal domain of MCT8 is poorly conserved, which complicates prediction of the deleteriousness of variants in this region. We studied the functional consequences of 5 novel variants within this domain and their relation to the clinical phenotypes. METHODS: We enrolled male subjects with intellectual disability in whom genetic variants were identified in exon 6 of SLC16A2. The impact of identified variants was evaluated in transiently transfected cell lines and patient-derived fibroblasts. RESULTS: Seven individuals from 5 families harbored potentially deleterious variants affecting the C-terminal domain of MCT8. Two boys with clinical features considered atypical for MCT8 deficiency had a missense variant [c.1724A>G;p.(His575Arg) or c.1796A>G;p.(Asn599Ser)] that did not affect MCT8 function in transfected cells or patient-derived fibroblasts, challenging a causal relationship. Two brothers with classical MCT8 deficiency had a truncating c.1695delT;p.(Val566*) variant that completely inactivated MCT8 in vitro. The 3 other boys had relatively less-severe clinical features and harbored frameshift variants that elongate the MCT8 protein [c.1805delT;p.(Leu602HisfsTer680) and c.del1826-1835;p.(Pro609GlnfsTer676)] and retained ~50% residual activity. Additional truncating variants within transmembrane domain 12 were fully inactivating, whereas those within the intracellular C-terminal tail were tolerated. CONCLUSIONS: Variants affecting the intracellular C-terminal tail of MCT8 are likely benign unless they cause frameshifts that elongate the MCT8 protein. These findings provide clinical guidance in the assessment of the pathogenicity of variants within the C-terminal domain of MCT8.

Original languageEnglish
Pages (from-to)539-553
Number of pages15
JournalThe Journal of clinical endocrinology and metabolism
Issue number2
Publication statusPublished - 23 Jan 2021


  • AHDS
  • Allan-Herndon-Dudley syndrome
  • MCT8
  • MCT8 deficiency
  • monocarboxylate transporter 8
  • thyroid hormone transport


Dive into the research topics of 'Clinical and Functional Consequences of C-Terminal Variants in MCT8: A Case Series'. Together they form a unique fingerprint.

Cite this